当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
GAVRETO (pralsetinib) 400 mg (once daily)
申请企业
BLUEPRINT MEDICINES CORP
药品名称
GAVRETO (pralsetinib) 400 mg (once daily)
承诺描述
Conduct a rodent fertility study investigating treated male rats (vehicle control and high dose only) mated to untreated female rats to evaluate the potential for pralsetinib to impair male fertility.